Literature DB >> 12163492

Stimulation of PrP(C) retrograde transport toward the endoplasmic reticulum increases accumulation of PrP(Sc) in prion-infected cells.

Florence Béranger1, Alain Mangé, Bruno Goud, Sylvain Lehmann.   

Abstract

Prion diseases are fatal and transmissible neurodegenerative disorders characterized by the accumulation of an abnormally folded isoform of the cellular prion protein (PrP(C)) denoted PrP(Sc). To identify intracellular organelles involved in PrP(Sc) formation, we studied the role of the Ras-related GTP-binding proteins Rab4 and Rab6a in intracellular trafficking of the prion protein and production of PrP(Sc). When a dominant-negative Rab4 mutant or a constitutively active GTP-bound Rab6a protein was overexpressed in prion-infected neuroblastoma N2a cells, there was a marked increase of PrP(Sc) formation. By immunofluorescence and cell fractionation studies, we have shown that expression of Rab6a-GTP delocalizes PrP within intracellular compartments, leading to an accumulation in the endoplasmic reticulum. These results suggest that prion protein can be subjected to retrograde transport toward the endoplasmic reticulum and that this compartment may play a significant role in PrP(Sc) conversion.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163492     DOI: 10.1074/jbc.M205110200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  49 in total

1.  Acute cellular uptake of abnormal prion protein is cell type and scrapie-strain independent.

Authors:  Christopher S Greil; Ina M Vorberg; Anne E Ward; Kimberly D Meade-White; David A Harris; Suzette A Priola
Journal:  Virology       Date:  2008-08-08       Impact factor: 3.616

2.  Low density subcellular fractions enhance disease-specific prion protein misfolding.

Authors:  James F Graham; Sonya Agarwal; Dominic Kurian; Louise Kirby; Teresa J T Pinheiro; Andrew C Gill
Journal:  J Biol Chem       Date:  2010-01-27       Impact factor: 5.157

3.  Proteasomal dysfunction and endoplasmic reticulum stress enhance trafficking of prion protein aggregates through the secretory pathway and increase accumulation of pathologic prion protein.

Authors:  Max Nunziante; Kerstin Ackermann; Kim Dietrich; Hanna Wolf; Lars Gädtke; Sabine Gilch; Ina Vorberg; Martin Groschup; Hermann M Schätzl
Journal:  J Biol Chem       Date:  2011-08-11       Impact factor: 5.157

Review 4.  Lysosomal Quality Control in Prion Diseases.

Authors:  Priyanka Majumder; Oishee Chakrabarti
Journal:  Mol Neurobiol       Date:  2017-04-18       Impact factor: 5.590

5.  The cellular prion protein with a monoacylated glycosylphosphatidylinositol anchor modifies cell membranes, inhibits cell signaling and reduces prion formation.

Authors:  Clive Bate; Alun Williams
Journal:  Prion       Date:  2011-04-01       Impact factor: 3.931

6.  Abnormal calcium homeostasis and protein folding stress at the ER: A common factor in familial and infectious prion disorders.

Authors:  Mauricio Torres; Gonzalo Encina; Claudi Soto; Claudio Hetz
Journal:  Commun Integr Biol       Date:  2011-05

Review 7.  Protein quality control in neurodegeneration: walking the tight rope between health and disease.

Authors:  E M Hol; W Scheper
Journal:  J Mol Neurosci       Date:  2007-03-24       Impact factor: 3.444

8.  Glimepiride reduces the expression of PrPc, prevents PrPSc formation and protects against prion mediated neurotoxicity in cell lines.

Authors:  Clive Bate; Mourad Tayebi; Luisa Diomede; Mario Salmona; Alun Williams
Journal:  PLoS One       Date:  2009-12-09       Impact factor: 3.240

9.  Inhibition of cholesterol recycling impairs cellular PrP(Sc) propagation.

Authors:  Sabine Gilch; Christian Bach; Gloria Lutzny; Ina Vorberg; Hermann M Schätzl
Journal:  Cell Mol Life Sci       Date:  2009-10-13       Impact factor: 9.261

10.  Identification of an intracellular site of prion conversion.

Authors:  Zrinka Marijanovic; Anna Caputo; Vincenza Campana; Chiara Zurzolo
Journal:  PLoS Pathog       Date:  2009-05-08       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.